Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shattuck LabsSTTK -4.13%42 EV-to-OCF is -10.90 as of Sep. 09, 2026. GuruFocus rates STTK with a GF Score™ of 42/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Shattuck Labs ranks better than 70.87% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Shattuck Labs's Enterprise Value is $447.23 Mil.
Shattuck Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-41.03 Mil. Therefore, Shattuck Labs's EV-to-OCF for today is -10.90.
The historical rank and industry rank for Shattuck Labs's EV-to-OCF or its related term are showing as below:
STTK'
s EV-to-OCF Range Over the Past 10 Years
Min: -75.59 Med: -1.09 Max: 1.65
Current: -10.9
During the past 8 years, the highest EV-to-OCF of Shattuck Labs was 1.65. The lowest was -75.59. And the median was -1.09.
STTK's EV-to-OCF is ranked better than 70.87% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs STTK: -10.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shattuck Labs's PE Ratio (TTM) for today is calculated as:
Shattuck Labs's share price for today is $6.505.
Shattuck Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shattuck Labs EV-to-OCF Related Terms
Shattuck Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Shattuck Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Shattuck Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shattuck Labs EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shattuck Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's EV-to-OCF falls into.
Shattuck Labs's current Enterprise Value is $447.23 Mil.
Shattuck Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shattuck Labs (STTK) has a EV-to-OCF of -10.90 as of Sep. 09, 2026. According to the industry distribution chart, Shattuck Labs ranks #409 out of 1404 companies in the Biotechnology industry, placing it in the top 29.1%.
Is Shattuck Labs' EV-to-OCF too high?
Shattuck Labs' current EV-to-OCF is -10.90. Based on the distribution chart, Shattuck Labs ranks #409 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' EV-to-OCF compare to BBOT and CTMX?
According to the Biotechnology industry distribution chart, Shattuck Labs ranks #409 out of 1404 companies for EV-to-OCF. This puts Shattuck Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Shattuck Labs's current EV-to-OCF is -10.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $6.51 — trading 519.5% above its estimated fair value. The current EV-to-OCF is -10.90. Shattuck Labs' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Shattuck Labs (STTK), the current EV-to-OCF is -10.90 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shattuck Labs (STTK) Overvalued in 2026?
Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued.
The current stock price of $6.51 is trading 519.5% above its estimated GF Value™ of $1.05.
GuruFocus considers Shattuck Labs to be Significantly Overvalued.
Key valuation signals for STTK:
EV-to-OCF: -10.90
GF Value™: $1.05 vs. price of $6.51 (519.5% above fair value)
No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score
Get the complete analysis for STTK
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STTK has been successfully added to your 
